Optison Європейський Союз - словацька - EMA (European Medicines Agency)

optison

ge healthcare as - perflutrén - echokardiografia - kontrastné médiá - tento liek je určený len na diagnostické účely. optison je transpulmonary echocardiographic kontrast prostriedok pre použitie u pacientov s podozrením alebo sídlo kardiovaskulárne ochorenia poskytnúť zakalenia srdcovej komory, zvýšiť vľavo-komorové-endocardial-vymedzenie hraníc s vyplývajúce zlepšenie v stene-motion vizualizácia. optison by sa mali použiť len u pacientov, kde štúdium bez kontrast doplnok je nepresvedčivá.

Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited) Європейський Союз - словацька - EMA (European Medicines Agency)

pemetrexed pfizer (previously known as pemetrexed hospira uk limited)

pfizer europe ma eeig - pemetrexed ditromethamine - carcinoma, non-small-cell lung; mesothelioma - kyseliny listovej analógy, antimetabolites - malígny pleurálna mesotheliomapemetrexed hospira uk limited v kombinácii s cisplatin je indikovaný na liečbu chemoterapiou insitného pacientov s unresectable malígny pleurálna mesothelioma. non-small cell lung cancerpemetrexed hospira uk limited v kombinácii s cisplatin je uvedené, za prvé-line liečbu pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer iné ako prevažne dlaždicových buniek histology (pozri smpc oddiel 5. pemetrexed hospira uk limited je označené ako monotherapy pre udržiavaciu liečbu lokálne pokročilým alebo metastatickým non-small cell lung cancer iné ako prevažne dlaždicových buniek histology u pacientov, ktorých ochorenie nie postupoval bezprostredne po platinum-založené chemoterapia (pozri smpc oddiel 5. pemetrexed hospira uk limited je označené ako monotherapy pre druhý riadok liečbu pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer iné ako prevažne dlaždicových buniek histology (pozri smpc oddiel 5.

Ceretec Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ceretec

ge healthcare as, nórsko - diagnostické rádiofarmaká - 88 - radiopharmaca

MYOVIEW Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

myoview

ge healthcare as, nórsko - technécium (99mtc) tetrofosmín - 88 - radiopharmaca

Rinvoq Європейський Союз - словацька - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.